Table 2.
Baseline characteristics of patients before and after propensity score matching in tumour sizes less than 5 cm.
| Total Set | Matched Set * | ||||||
|---|---|---|---|---|---|---|---|
| Tumour Size < 5 cm | NAR Group | AR Group | p-Value | SMD | NAR Group | AR Group | SMD |
| n = 123 | n = 478 | n = 117 | n = 224 | ||||
| Age | |||||||
| <50 years | 31 (25.2) | 149 (31.2) | 0.433 | 0.133 | 31 (26.5) | 68 (30.4) | 0.100 |
| 50–60 years | 59 (48.0) | 209 (43.7) | 56 (47.9) | 97 (43.3) | |||
| >60 years | 33 (26.8) | 120 (25.1) | 30 (25.6) | 59 (26.3) | |||
| Sex (male/female) | 103 (83.7%)/20 | 368 (77.0%)/110 | 0.105 | 0.171 | 97 (82.9%)/20 | 180 (80.4%)/44 | 0.066 |
| Primary liver disease | |||||||
| HBV | 92 (74.8) | 395 (82.6) | 0.032 | 0.241 | 89 (76.1) | 175 (78.1) | 0.051 |
| HCV | 15 (12.2) | 27 (5.6) | 13 (11.1) | 22 (9.8) | |||
| NBNC | 16 (13.0) | 56 (11.7) | 15 (12.8) | 27 (12.1) | |||
| Preoperative TACE | 27 (22.0) | 97 (20.3) | 0.685 | 0.041 | 24 (20.5) | 55 (24.6) | 0.097 |
| AFP (ng/mL) | |||||||
| <100 | 80 (65.0) | 294 (61.5) | 0.771 | 0.073 | 76 (65.0) | 139 (62.1) | 0.062 |
| 100–1000 | 27 (22.0) | 116 (24.3) | 25 (21.4) | 51 (22.8) | |||
| >1000 | 16 (13.0) | 68 (14.2) | 16 (13.7) | 34 (15.2) | |||
| Platelet | |||||||
| <150 | 77 (62.6) | 290 (60.7) | 0.695 | 0.040 | 73 (62.4) | 131 (58.5) | 0.080 |
| ≥150 | 46 (37.4) | 188 (39.3) | 44 (37.6) | 93 (41.5) | |||
| Log-transformed AST | 3.62 ± 0.45 | 3.59 ± 0.42 | 0.498 | 0.067 | 3.62 ± 0.45 | 3.61 ± 0.43 | 0.025 |
| Total bilirubin | |||||||
| <1.5 | 110 (89.4) | 444 (92.9) | 0.203 | 0.122 | 106 (90.6) | 207 (92.4) | 0.065 |
| ≥1.5 | 13 (10.6) | 34 (7.1) | 11 (9.4) | 17 (7.6) | |||
| Albumin | 3.70 ± 0.41 | 3.80 ± 0.39 | 0.008 | 0.265 | 3.73 ± 0.38 | 3.76 ± 0.38 | 0.073 |
| PT (INR) | 1.10 ± 0.10 | 1.28 ± 4.43 | 0.669 | 0.055 | 1.10 ± 0.09 | 1.09 ± 0.09 | 0.057 |
| ICG R15 | |||||||
| <15 | 74 (60.2) | 341 (71.3) | 0.017 | 0.237 | 74 (63.2) | 144 (64.3) | 0.022 |
| ≥15 | 49 (39.8) | 137 (28.7) | 43 (36.8) | 80 (35.7) | |||
| Number of tumours | |||||||
| Solitary | 107 (87.0) | 428 (89.5) | 0.420 | 0.079 | 104 (88.9) | 191 (85.3) | 0.108 |
| Multiple | 16 (13.0) | 50 (10.5) | 13 (11.1) | 33 (14.7) | |||
| Macrovascular invasion | 9 (7.3) | 34 (7.1) | 0.938 | 0.008 | 8 (6.8) | 13 (5.8) | 0.043 |
| Microvascular invasion | 11 (8.9) | 47 (9.8) | 0.766 | 0.031 | 10 (8.5) | 20 (8.9) | 0.014 |
| Edmondson–Steiner grade | |||||||
| I–II | 60 (48.8) | 273 (57.1) | 0.097 | 0.168 | 58 (49.6) | 112 (50.0) | 0.009 |
| III–IV | 63 (51.2) | 205 (42.9) | 59 (50.4) | 112 (50.0) | |||
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; AR, anatomic resection; HBV, hepatitis B virus; HCV, hepatitis C virus; ICG R15, indocyanine green retention rate at 15 min; INR, international normalised ratio; NAR, non-anatomic resection; NBNC, non-HBV non-hepatitis C virus; PT, prothrombin time; SMD, standardised mean difference; TACE, transcatheter arterial chemoembolisation. * Propensity score matching was used with 1:n greedy nearest-neighbour algorithm within specified calliper widths. SMD < 0.1 is considered to be balanced.